Genitourinary Cancer

The FDA approved nivolumab for adjuvant treatment of patients with surgically resected, high-risk urothelial carcinoma, according to the agent’s manufacturer.

The FDA approved belzutifan for treatment of cancers associated with von Hippel-Lindau disease.

The FDA approved the combination of pembrolizumab and lenvatinib for first-line treatment of adults with advanced renal cell carcinoma.

The FDA granted priority review to pembrolizumab as adjuvant therapy for certain patients with renal cell carcinoma, according to the agent’s manufacturer.

Members of American Society for Radiation Oncology elected three new officers to ASTRO’s board of directors.

Mani Menon, MD, has been named chief of strategy and innovation in Mount Sinai Health System’s department of urology.

High urinary levels of cotinine appeared associated with a fourfold increased risk for recurrence of nonmuscle invasive bladder cancer in smokers, according to a study presented during the virtual European Association of Urology Congress.

Pembrolizumab plus axitinib continued to exhibit superior efficacy to sunitinib as first-line therapy for advanced clear cell renal cell carcinoma, according to long-term follow-up of the randomized phase 3 KEYNOTE-426 trial.

Shilpa Gupta, MD, has been appointed director of genitourinary medical oncology at Taussig Cancer Institute and co-leader of the genitourinary oncology program at Cleveland Clinic.

Transurethral resection of bladder tumor plus systemic therapy induced clinical complete response among a large subset of patients with muscle-invasive bladder cancer, according to phase 2 study results.